9 June 2023 in Journal of Cellular and Molecular Medicine
Tensin 1 was originally described as a focal adhesion adaptor protein, playing a role in extracellular matrix and cytoskeletal interactions. Three other Tensin proteins were subsequently discovered, and the family was grouped as Tensin. It is now recognized that these proteins interact with multiple cell signalling cascades that are implicated in tumorigenesis. To understand the role of Tensin 1–3 in neoplasia, current molecular evidence is categorized by the hallmarks of cancer model. Additionally, clinical data involving Tensin 1–3 are reviewed to investigate the correlation between cellular effects and clinical phenotype. Tensin proteins commonly interact with the tumour suppressor, DLC1. The ability of Tensin to promote tumour progression is directly correlated with DLC1 expression. Members of the Tensin family appear to have tumour subtype‐dependent effects on oncogenesis; despite numerous data evidencing a tumour suppressor role for Tensin 2, association of Tensins 1–3 with an oncogenic role notably in colorectal carcinoma and pancreatic ductal adenocarcinoma is of potential clinical relevance. The complex interplay between these focal adhesion adaptor proteins and signalling pathways are discussed to provide an up to date review of their role in cancer biology.
8 October 2026 in Clinical Otolaryngology
Objectives: To report early outcomes following implementation of a da Vinci Single‐Port transoral robotic surgery (SP‐TORS) programme in the United Kingdom. To provide contextual benchmarking, outcomes were compared with a historical institutional cohort treated using transoral laser microsurgery (TLM). Design: Retrospective institutional series with comparison against a historical cohort using stabilised inverse‐probability‐of‐treatment weighting. Setting: High‐volume UK Tertiary Head and Neck Centre. Participants: All patients undergoing SP‐TORS between April 2024 and September 2025. Comparative analyses were limited to oncological resections and included 33 SP‐TORS and 61 TLM cases. Main Outcome Measures: Feasibility, peri‐operative safety, postoperative haemorrhage, return to theatre, mortality, length of stay, time to oral diet, margin status and adjuvant therapy use. Results: Sixty‐six patients underwent SP‐TORS. All procedures were completed transorally without unplanned conversion or peri‐operative mortality. Postoperative haemorrhage occurred in 4.5%, with one return to theatre. Length of stay did not differ between groups. Time to oral diet was longer following SP‐TORS (adjusted ratio 1.51, p = 0.005). ASCO‐defined involved margins were similar (OR 0.30, 95% CI 0.06–1.56; p = 0.15), whereas specimen ink‐positive margins were less frequent following SP‐TORS (OR 0.31, 95% CI 0.11–0.91; p = 0.03). A sensitivity analysis using propensity‐matched T1/T2 pairs demonstrated a consistent directional effect, though this did not reach significance in the smaller matched cohort. Adjuvant therapy use was comparable. Conclusion: SP‐TORS implementation in a high‐volume UK centre was feasible and safe during early adoption, with low complication rates. Peri‐operative and early functional outcomes were broadly comparable with TLM. Although specimen ink‐positive margins were less frequent following SP‐TORS, interpretation should be cautious given the historical comparator and associated differences in departmental workflow. These findings support safe integration of SP‐TORS into transoral surgical practice and justify prospective evaluation.
4 May 2026 in Otolaryngology–Head and Neck Surgery